hapabapa
Roche (RHHBY) CEO Thomas Schinecker stated that the recent U.S. drug pricing deals will likely lead to higher prices for new drugs in Switzerland.
CEO of the Swiss pharma giant Thomas Schinecker explained that Switzerland has the most to gain